Of note, an in vivo screening based on CRISPR/Cas9 has identified protein tyrosine phosphatase nonreceptor type 2 (PTPN2) as a novel target for cancer immunotherapy.257 In the future, this innovative approach could also be used to develop personalized cancer therapies based on genotype-specific targets.258. This evidence concerns the gene PTPN2 and cancer.